| Document |
Document Title |
|
WO/2019/177163A1 |
This application provides: a novel mouse artificial chromosome vector that is stable in rodent cells or tissues or rodent individuals, specifically a mouse artificial chromosome vector derived from a mouse chromosome selected from the gr...
|
|
WO/2019/177902A1 |
The present disclosure relates to bifunctional compounds, which find utility as modulators of Burton's Tyrosine Kinase (BTK). In particular, the present disclosure is directed to bifunctional compounds. One end of a bifunctional compound...
|
|
WO/2019/171377A1 |
The present disclosure provides compositions and methods for providing a cell replacement therapy to treat various diseases, including pancreatic diseases and diabetes. Specifically, the disclosure provides three-dimensional (3D) cell cl...
|
|
WO/2019/173224A1 |
The present disclosure provides compounds that modulate protein function and/or restore protein homeostasis. The disclosure provides methods of modulating protein-mediated diseases, disorders, conditions, or responses. Compositions, incl...
|
|
WO/2019/168324A1 |
The present invention relates to a composition for preventing and treating hormonal disorders or andropause in males, containing, as an active ingredient, a herbal medicine extract comprising a combination of compounds comprising flavono...
|
|
WO/2019/169089A1 |
Described are macro-capsules, barriers, and devices that can be used to prepare therapeutic cell implants, methods of encapsulating therapeutic cells, and methods of using the encapsulated cells in the treatment of disease.
|
|
WO/2019/166984A1 |
The subject matter of the invention is a composition containing myo-inositol and D-chiro-inositol for use in method of weight reduction, improvement of metabolic and hormonal parameters and improvement of condition of skin in women with ...
|
|
WO/2019/162425A1 |
The present invention relates to a glycan composition useful as nutritional supplement, such as for infant formula supplement and as nutraceutical products and a method of preparation thereof.
|
|
WO/2019/154237A1 |
The present invention relates to a co-crystal of calcifediol and vitamin D3, a preparation method therefor and use thereof. In the co-crystal, the molar ratio of calcifediol to vitamin D3 is 1: 1. The co-crystal of calcifediol and vitami...
|
|
WO/2019/156199A1 |
The present invention addresses the problem of providing a novel drug for the prevention of autoimmune diseases, the suppression of the progression of the symptoms of autoimmune diseases, the suppression of the recurrence of autoimmune d...
|
|
WO/2019/151353A1 |
A method for producing a preparation for injection, said method comprising: a first step for performing at least one treatment selected from the group consisting of a treatment whereby benzyl benzoate is mixed with an antioxidant, a trea...
|
|
WO/2019/151883A1 |
The invention relates to a novel use of benzazepine, benzoxazepine, benzothiazepine-N-acetic acid and phosphono-substituted benzazepinone derivatives having both neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP), and ...
|
|
WO/2019/149178A1 |
The present invention relates to a glucopyranosyl derivative and a use thereof. In particular, the present invention relates to a glucopyranosyl derivative that is used as an inhibitor of sodium-dependent glucose transporters (SGLTs), pa...
|
|
WO/2019/147718A1 |
Post-bariatric hypoglycemia (PBH) is an increasingly-recognized complication of gastric bypass surgery. Current therapeutic options have suboptimal efficacy. Small doses of stable liquid glucagon can be used to treat or prevent post-bari...
|
|
WO/2019/146612A1 |
The present invention provides an excellent composition (e.g., a drug, a quasi drug, a cosmetic) for skin diseases treatment use. The composition for skin diseases treatment use according to the present invention contains an exosome secr...
|
|
WO/2019/144835A1 |
The present invention relates to a pharmaceutical composition of a substituted pyridazinone compound and use thereof. The substituted pyridazinone compound is a compound as represented by formula (I), or a pharmaceutically acceptable sal...
|
|
WO/2019/137138A1 |
The present invention relates to a use of human GPNMB protein or an antagonist or agonist thereof. It has been found that GPNMB gene, RNA, and protein can be used as biomarkers for diagnosing a metabolic disease, such as obesity, diabete...
|
|
WO/2019/131998A1 |
The present invention addresses the problem of providing an astatine solution that can be used in radionuclide therapy for the treatment of thyroid disease or the like, and a method for producing the same. The present invention provides:...
|
|
WO/2019/131458A1 |
Provided are a compound represented by formula (1) or a salt thereof, and a medicine including the same. [In the formula, X1 represents a hydrogen atom or a halogen atom, X2 represents a fluorine atom or a nitrile group, and X3 represent...
|
|
WO/2019/120079A1 |
The present invention provides a thioxoimidazole dione compound as shown in formula (I). The compound can act as an androgen receptor antagonist and can be used to prepare a drug for treating an androgen receptor-related disease or disor...
|
|
WO/2019/124411A1 |
A medicinal composition for preventing or treating secondary hyperparathyroidism under maintenance dialysis, said medicinal composition comprising 3-{[(2S)-2-amino-2-carboxyethyl]carmaboylamino}-5-chloro-4-m
ethylbenzenesulfonic acid or ...
|
|
WO/2019/123427A1 |
Provided herein are methods of treating, preventing, and managing metabolic or cardiovascular disorders and methods of reducing cardiovascular risk with FGF21 protein variants, including Fc-FGF21 variant fusion proteins.
|
|
WO/2019/109124A1 |
There is provided compositions and methods for modulating the fenestration porosity, fenestration frequency or fenestration diameter of liver endothelial cells. In particular compositions comprising conjugates of quantum dots and a thera...
|
|
WO/2019/104391A1 |
The present invention relates to peptides, compositions and methods for the treatment, prevention or monitoring the progression of type 1 diabetes.
|
|
WO/2019/104748A1 |
Disclosed is the use of the compound as shown in formula Ⅰ or a stereoisomer, a geometric isomer, a tautomer, a nitrogen oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof in preparing dr...
|
|
WO/2019/103129A1 |
The present invention addresses the problem of providing a technique for efficiently producing a cell mass including pituitary tissue from pluripotent stem cells. A method for producing a cell mass including pituitary tissue, the method ...
|
|
WO/2019/104225A1 |
Provided herein are microspheres (e.g., single emulsion microspheres) comprising a therapeutic compound or pharmaceutically acceptable salt thereof, one or more polymers, and optionally a polyol, as well as methods of preparation, method...
|
|
WO/2019/101035A1 |
A glucagon analogue for treating metabolic diseases, the structure formula is as follows: H-X2-X3-GTFTSD-X10-SKYLD-X16-X17-AAQ-DFVQWLMN-X29-Xz or H-S-Q-GTFTSD-Y-SKYLD-X16-X17-AAQ-DFVQWLMN-X29-Xz-NH2. The described glucagon analogue has a...
|
|
WO/2019/100503A1 |
The present invention provides a use of an agent for preparing a medicament for inhibiting microRNA-708. The medicament is used for at least one of the following: reducing intracellular triglyceride content, inhibiting differentiation of...
|
|
WO/2019/095027A1 |
The field of application is the pharmaceutical industry and the area of medicinal formulations for transdermal administration. Use of drugs with a molar mass below 500 that are soluble in propylene glycol and specifically the drugs testo...
|
|
WO/2019/098238A1 |
Provided is an activator for a peroxisome proliferator-activated receptor α which contains: a compound represented by general formula (I); a tautomer, stereoisomer, or pharmaceutically acceptable salt of said compound; or a solvate of a...
|
|
WO/2019/099725A1 |
Disclosed herein are compositions and methods useful for manufacturing SC- cell, and isolated populations of SC- cells for use in various applications, such as cell therapy.
|
|
WO/2019/092449A1 |
The present invention relates to a construct comprising a C13 to C27 fatty acid non- covalently bound to a hydrophobic region of a carrier particle, methods of manufacture, and uses thereof.
|
|
WO/2019/094292A1 |
The present invention includes a pharmaceutical composition and method of making and using comprising one or more thyroid hormones or analogs thereof, wherein a first portion of thyroid hormone is formulated for modified release and a se...
|
|
WO/2019/086720A1 |
The present invention relates to novel dihydropyridine derivatives of formula (I): as modulators of nuclear receptors selected from androgen receptor and glucocorticoid receptor, to processes for their preparation, to pharmaceutical comp...
|
|
WO/2019/088010A1 |
The present invention provides a testosterone-containing transdermally administrable preparation having excellent testosterone cutaneous permeability and excellent physical properties. More specifically, the present invention provides a ...
|
|
WO/2019/081302A1 |
The present invention relates to novel substituted 1,2,4-triazole derivatives, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions...
|
|
WO/2019/082910A1 |
Provided are: a V2 receptor antagonist which has high water solubility and which is particularly suitable for injections; and a medicine containing the V2 receptor antagonist or the like. The present invention is a compound represented b...
|
|
WO/2019/080671A1 |
A crystalline structure of leonurine and use thereof in preparing drugs. Six crystals of leonurine sulfate having different structures, of which, two are hydrates, two are amorphous, one is a methanolate, and one is an ethanolate. The cr...
|
|
WO/2019/081299A1 |
The present invention relates to novel amine substituted 1,2,4-triazole derivatives, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compos...
|
|
WO/2019/080811A1 |
The present invention relates to a crystal form of a compound (I) and a preparation method therefor, a pharmaceutical composition comprising the crystal form, and the use of the crystal form in the preparation of a preparation comprising...
|
|
WO/2019/079279A1 |
Disclosed are methods of purifying the compound (22E)-(247R)-2-methylene- 22-dehydro-1α,24,25-trihydroxy-19-nor-vitamin D3 to obtain the compound in crystalline form. The methods typically include the steps of dissolving (22E)-(24R)-2-m...
|
|
WO/2019/078116A1 |
The purpose of the present invention is to provide a sweetness receptor antagonist that is useful in the prevention or treatment of, for example, metabolic syndrome, diabetes or obesity. A sweetness receptor antagonist comprising a com...
|
|
WO/2019/073433A1 |
Combination of dry extract of Rhodiola, dry extract of Tribulus terrestris, dry extract of Undaria pinnatifida, Moringa oleifera, folic acid and vitamin B12 in the form of food supplement for mitigating woman's disorders caused by ageing.
|
|
WO/2019/065958A1 |
Provided is a drug for the prevention or treatment of hyperphosphatemia and diseases associated with hyperphosphatemia. A drug for the prevention or treatment of hyperphosphatemia and diseases associated with hyperphosphatemia, said drug...
|
|
WO/2019/060051A1 |
The present invention provides a compound of formula (I) or a salt thereof: (I) wherein X, L, V, R1, R2, R3 and R4, are as defined herein. These compounds are inhibitors of 11-hydroxysteroid dehydrogenase type 2 (11-HSD-2) and are used t...
|
|
WO/2019/058263A1 |
The present invention provides peptides comprising a cargo peptide and a cell penetrating peptide that bind ERp44, peptides comprising a cargo peptide and a cell penetrating peptide that increase secretion of adiponectin from cells and m...
|
|
WO/2019/057820A1 |
The invention features methods of using sFGFR3 polypeptides to treat abnormal visceral fat deposition and the conditions associated with abnormal visceral fat deposition.
|
|
WO/2019/059303A1 |
This liquid pharmaceutical preparation for subcutaneous administration in humans contains 28.2 µg of teriparatide or salt thereof (component 1) in terms of teriparatide in a single dose, wherein the concentration of component 1 is 80 to...
|
|
WO/2019/059302A1 |
The present invention provides, as a liquid pharmaceutical preparation of teriparatide or a salt thereof and having excellent physical properties, a liquid pharmaceutical preparation containing teriparatide or a salt thereof and at least...
|
